



Make Money In Up or Down Markets

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Charles Moskowitz Michael King

Charles Moskowitz Discussion

Week 35 started off with one of the worst single trade loss in the NVDA 170 calls of \$386 but came back strong to finish on the plus side with a gain of \$352 bringing YTD performance to another new high of \$12,806. On top of that gain are two open positions from the two 100% Up Rule liquidations with equity of roughly \$1000. We have a total of 3 long and 1 short position with funds in use of only \$472.

Clearly Harvey was the star for the week for the oil and distillates markets with too much oil that couldn't be refined; so as the oil declined early in the week, the RBOB (unleaded gas) climbed from \$1.64/gallon to a high of \$1.923, it closed + .081 but \$.176 off the highs. On the geopolitical side, North Korea is really getting to be a problem. While we've always had *somewhat* intelligent enemies in the nuclear family, or at least those who believed in MAD (for those who are too young to know or remember), Mutually Assured Destruction, we don't really know how Kim feels about it. The gold was the main beneficiary of the issue with the weekly range of 1293-1330 and closing @ \$1326.60. This was the first time since the break after Election Day (1338 to 1123) when we dropped 16% in just 6 weeks to make it through 1295. Technically the move above 1295 is important, but mixing the fundamentals and technical, the real economy doesn't feel that great and overhead resistance from right here to 1340 makes it too late to jump in now. If we come in a bit and can hold 1285-90, a move to 1380 is possible.

The indexes have shown a bit of divergence with the QQQ and NASDAQ both making a new weekly high close, while the

DJIA, Russell and in particular the Transports unable (so far) to break out. This has happened several times with the Transports and they have caught up, so I don't concern myself. Another indicator that I rely on for undercurrent is the A.A.I.I. sentiment numbers (a contrary indicator) that is showing only a 25% bullish (LT average 38.4), 39.9% bearish (30.30 LT average) and neutral of 35% (31 average). My interpretation is that only 25% bullish means that 75% of everyone thinks we're staying even or lower and as said here repeatedly, "Everyone is **NEVER** right").

While I will stay away from oil stocks, retail (XRT) is looking like it may be making a double bottom with early 2016 and may be running up against easier comps, and financials are oversold. I can't get really bullish with the 10 year unable to move higher and flattening the yield. It is my opinion that you can't have a healthy bull move without financials *at least* coming along. Last but not least is the biopharma group has made a strong move both on fundamental and M/A sides. We seem to be back in the "it's easier to buy new approved products" than to do all of the R&D yourself. The GILD purchase of KITE was just the one that got the most press, but there have been and will be (my opinion) many more.

CAM

All trades were based on your participation in the texting service to receive updates.

DATE		PRICE	COST	PROCEEDS	RESULTS
08/31	Sold 4 IWM September 140 Calls	1.22		488	
08/31	Sold 4 IWM Sept 138 Calls(100% Profit Rule)	2.40		960	480 Gain
08/31	Sold 3 CSTM Sept \$ 10 Calls (100% Profit Rule) leaves 3 lots Long	1.60		480	240 Gain
08/28	Bought 8 IWM Sept 138 Calls	1.20	960		
08/28	Sold 8 NVDA Sept 1 st \$170 Calls	0.46		368	368 Loss
08/25	Bought 8 NVDA Sept 1 st \$170 Calls	0.92	736		
08/23	Bought 6 CSTM September \$10 Calls	0.80	480		
08/08	Bought 8 SKYW Sept \$ 40 Calls	0.30	240		

NEW TRADES OPTIONS ACCOUNT

- (1) BUY 8 XRT SEPTEMBER \$ 39.50 CALLS @ \$ 0.56
- (2) BUY 8 ALB SEPTEMBER \$ 120 CALLS @ \$ 0.80

NEW TRADES \$ 100 000 ACCOUNT:

- (1) BUY 16 XRT SEPTEMBER \$ \$ 39.50 CALLS @ \$ 0.56
- (2) BUY 16 ALB SEPTEMBER \$ 120 CALLS @ \$ 0.80

SELL STOP OF OPEN POSITION:

- (1) SELL 150 LABU @ \$ 72.47X (STOP)

MARKET LABORATORY - WEEKLY CHANGES

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect

Dow 21,987.56 +173.89 +0.80%	Nasdaq 6435.33 +169.69 +2.71%	S&P 500 2476.55 +33.50 +1.37%	Transportation 9356.02 +222.27 +2.43%	Russell 2000 1413.57 +36.12 +2.62%	Nasdaq100 5987.90 +165.37 +2.84%
Gold (spot) 1324.50 +32.00 +2.5%	Silver Sept 17.81 +0.68 +4.0%	Crude Aug 47.29 -0.58 -1.2%	Heating Oil 1.7468 +0.123 +7.6%	Unleaded Gas 1.7479 + 0.207 +13.4%	Natural Gas 3.07 +0.146 +5.0%
VIX 10.13 -1.15 -10.2%	Put/Call Ratios S&P 100 99/100's -20/100's	Put/Call Ratios CBOE Equity 57/100's -4/100's	Bonds 156-15 -0-01 2.95% 0-024%	10 Yr. Note 126-305+0-25 2.26%-030%	Copper 3.118 +0.06 +2.0%
CRB Inflation Index 180.95 +3.12 +1.8%	Barron's* Confidence 77.0 +1.0	S&P100 1095.25 +15.23 +1.41%	5 YR Note 118-21 -0+02 1.79%-0.05%	Dollar 92.85 +0-11 +0.1%	DJ Utilities 740.95 -5.53 -0.74%
AAll Confidence Index Average	Bullish 25.0% -3.1% 38.4%	Bearish 39.9% +1.6% 30.30%	Neutral 35.1% +1.5% 30.96%	M1 Money Supply +7.86% Aug 21st	M2 Money Supply +4.97% Aug 21st

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect * Component Change is in the Confidence Index

	SUPPORT	RESISTANCE
S&P 500	2446	2491
NASDAQ (QQQ)	143.30	148.20
Trans	9170	9590
DOW	21,810	22,210
TLT	124.80	129.70

Each Stock is allocated a theoretical \$ 5,000 share of the portfolio

		Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/(\$ 920Los)
LABU	150	65.76	08/28			
BBRY	400	11.21	06/07			
GLYC	400	12.66	06/01			
HL	500	5.72	06/01			
GSAT	1500	2.30	05/18			
SLV	300	15.78	05/15			
AGQ	150	40.39	04/07			
NUGT	75	35.68	03/13			
RWM	100	50.60	11/21			
SPXU	200	22.88	11/14			
AMBA	100	63.75	10/13			
MOS	200	27.53	05/02			
EYES	500	5.04	04/04			
EYES	1000	6.49	12/28			
TWTR	200	28.51	10/28			
MOS	100	43.55	08/14			
HL	500	3.95	05/03			
SAN	600	8.40	12/16			
TEXQY	200	6.56	7/11			
REPR*		0.22	10/22/12			
5000						

Recommendations will be both listed in this letter and texted to members. Previous closed out trades can be seen on each preceding weekly market letter. X means stop loss

Aug 28th;21st;14th;7th;July31st;24th;17th;10th;3rd;June26th;19th;12th;5th;May9th;22nd;15th;8th;1st;Aprilth;24th;17th

SCO means stop close only
Additional New Options Trades: will be texted

Large Account: Additional trades and stop losses will be Texted and E-Mailed
The new number has been provided. Call Dave Rodgers if there are problems at (832) 236- 3640.
Or Mike King 702 650 3000; Charles Moskowitz 617 827 1296

There were three closed out options positions last week, two winners and one losing position, gaining \$704.00 in options trading. There were no closing stock trades: The one new position is the 150 shares of LABU bought at \$ 65.76, requiring new funds of \$ 9,864.00. There are three remaining option positions, the 15 SKYW September \$40 Calls bought at \$ 0.30 costing \$450.00; the 6 remaining CSTM September \$ 10 Calls bought at \$ 0.80 and 8 IWM Sept 138 Calls bought at \$ 1.20. The net gain for the week was \$ 704. The total margin requirement for options is \$ 464.00. The options expire on the third Friday of each month unless otherwise posted. The Stock table has the following 19 positions: AGQ, BBRY, EYES (2), GLYC, GSAT, HL (2), MOS (2), NUGT, REPR, RWM, SAN, SCO, SLV, SPXU, TEXQY, TWTR,

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically. Money management is based on a hypothetical \$ 100,000.00. The 19 stock positions would cost \$ 79,338.00. The LABU added last week increases the margin requirement by \$ 9,864.00 to \$ 89,202.00. The open long options position; the SKYW September \$ 40

Calls require \$ 450.00; the 6 CSTM Calls need \$ 480, while the requirement for the 8 IWM Sept 138 Calls 170 Calls is \$ 960.00, which totals \$ 1890. The short IWM Sept 140 Calls provide a credit of \$ 976. The net comes to a requirement of \$ 914; when combined with the stock requirement of \$ 89,202.00 equals \$ 90,116.00 which leaves excess cash of \$ 9,884.00.

YEAR TO DATE the \$100,000 Account has had 148 closed out trades between stocks, options and covered writes versus stock positions. There were no closed stock positions last week. There was an improvement in open trade equity (+ \$ 3,017) on the open positions to a minus \$ 17,277.00. On the former closed positions, 101 were gains and 47 were losses. Gains to date equal \$53,215.00; losses equal \$18,689.00, for a net gain of \$34,526.00. This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Previous Week's Recommendations and Rules for the \$ 100,000 account

- **Text UPDATES to number provided**
- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated.
- When the option has doubled sell half the position.
- Stop Loss protection is half if Option trades above 50 Cents or offered with each trade.
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
- Subscribers can follow us on Twitter or call 702 650 3000 for up to date information.

Note: Closed out stock and option positions can be found in previous weekly market letters: Such as

Aug 28th; 21st; 14th; 7th; July 31st; July 24th; 17th; 10th; 3rd; June 26th; 19th; 12th; 5th; May 29th; 22nd; 15th; 8th; 1st; April 24th; 17th

Option	COST	Date	Sold	Date	Profit/(Loss)
IWM Sept 138 8 lots	<u>Calls</u> <u>1.20</u>	08/28/17	2.40 Sold Half 8 lots 100% up Rule	08/31/2017	\$ 960
IWM Sept 140 8 lots Short	<u>Calls</u>		1.22	08/31/2017	\$ 976 Credit
NVDA Sept 1st 170 16 lots	<u>Calls</u> <u>0.92</u>	08/25/17	0.46 (50% Down Rule)	08/28/2017	(\$ 736)
CSTM Sept 10 6 lots	<u>Calls</u> <u>0.80</u>	08/23/17	1.60 Sold Half 6 lots 100% up Rule	08/31/2017	\$ 480
SKYW Sept 40 15 lots	<u>Calls</u> <u>0.30</u>	08/08/17			

This week's Economic Numbers and Earnings Releases: Before the Open on top of the Row; After the Close below the Economics information and News releases: Space is limited:

MONDAY	Labor Day Holiday-U.S. Markets Closed
TUESDAY	<p>Napco Security Systems NSSC (0.19 vs 0.18)</p> <p>10:00 hrs Factory Orders July (-3.2% vs +3.0%)</p> <p>Casey's General CASY (1.45 vs 1.70) Hewlett Packard Enterprise HPE (0.26 vs 0.49) At Home Group HOME (0.17 vs 0.13) Dave & Busters PLAY (0.55 vs 0.50)</p>
WEDNESDAY	<p>HD Supply Holdings HDS (0.64 vs 0.65) Navistar NAV (0.27 vs -0.42) JinkoSolar Holding JKS (0.67 vs 2.04) Fred's FRED (-0.17 vs -0.18) Francesca's FRAN (0.19 vs 0.27)</p> <p>07:00 hrs MBA Mortgage Applications Index 09/02 (NA vs -2.3%) 08:30 hrs GDP 08:30 hrs Trade Balance July (-44.6 Bln vs -\$ 43.6 Bln) 10:00 hrs ISM Services August (+55.2 vs 53.9) 10:30 hrs Crude Inventories 09/02 (NA vs -5.4Mln) 14:00 hrs Fed's Beige Book release September (NA)</p> <p>ABM Industries ABM (0.54 vs 0.54) Restoration Hardware RH (0.47 vs 0.44) NCI Building Systems NCS (0.32 vs 0.33) KornFerry KFY 0.53 vs 0.52) Quanex NX (0.32 vs 0.30)</p>
THURSDAY	<p>Barnes & Noble BKS (-0.12 vs -0.07) Conn's CONN (-0.03 vgs -0.04) Donaldson DCI (0.53 vs 0.46) John Wiley & Sons JW.A (0.62 vs 0.52) Hovnanian HOV (-0.01 vs 0.00)</p> <p>08:30 hrs Productivity- Revised 2nd Qtr (+ 1.2% vs +0.9%) 08:30 hrs Unit Labor Costs - Revised 2nd Qtr(0.3% vs 0.6%) 08:30 hrs Initial Claims 09/02 (239K vs 236K) 08:30 hrs Continuing Claims 08/26 (NA vs 1942K) 10:30 hrs Natural Gas Inventories) 09/02 (NA vs 30bcf) 15:00 hrs Consumer Credit July (\$ 15.0Bln vs \$ 12.4 Bln)</p> <p>American Outdoor Brands AOBC (0.11) Finisar FNSR (0.40 vs 0.38) Science Applications SAIC (0.91 vs 0.85) REV Group REVG (0.31) Tailored Brands TLRD (0.88 vs 0.99)</p>
FRIDAY	<p>Kroger KR (0.39 vs 0.47) Eros International EROS (0.00 vs 0.03)</p> <p>10:00 hrs Wholesale Inventories July (0.4% vs 0.7%)</p> <p>Layne Christiansen LAYN (-0.14 vs -0.21) The U.S. Oil Rig Count decreased by 4 Rigs to 759. The Nat Gas Rig count increased by 1 to a total of 182, there is one miscellaneous, making a total rig count 946. There are 455 more rigs in operation this year, up from 2016. Crude closed lower at \$48.51 off \$ 0.31 or -0.6%. Natural Gas closed the week falling \$ 0.0873 or -2.9% at \$ 2.8930.</p>

—

FUNDAMENTALS

The Dow Jones Industrials (21,987.56 +173.89 or + 0.80%) catapulted to test the all-time highs rallying for a second consecutive week at a time when the markets usually move lower in the doldrums of August and September. The Russell 2000 surged 36.12 points or 2.62% on top of the previous weeks' gains of 19.66 points for a total of 55.78 points gained in the two weeks or + 4%. The Russell 2000 ETF, IWM (137.07 + \$ 2.15 or + 1.6%) led all indexes for the week after having plummeted to its 200 day moving average at about 134.12, making a possible double bottom and holding. It then proceeded to rally to 137.18, breaking above its declining 13-day price moving average. As the historically difficult month of September approaches, many stocks are struggling to hold relatively elevated levels.

The S&P 500 (2476.55) + \$ 33.50 or 1.37% was rebounded making back almost all of its losses the previous week. The North Korean news last Tuesday of its firing a ballistic missile over Japanese island

of Hokkaido had an unsettling effect on stocks which made their low on the news at 2428.20 which proved to be the low point for the week, from which there was a substantial rally to 2476.25 to test the all-time highs at 2490.87 set August 8th.

The Nasdaq Composite (6435.33) + \$ 169.69 or +2.71% moved back into record territory, gaining 170 points to close at 6,435.33, or + 2.71%. The QQQ at \$ 146.00 had five consecutive up-days rallying each day of the week totaling \$ 4.03 or 2.93%. For the entire month of August the QQQ is up \$ 2.61 or 1.8%, not bad at a time of usual declines.

The Dow Jones Transportation Average (9356.02) + \$ 222.27 or +2.43% was the leader, the best performing index last week after being the worst the previous week. The Dow Jones Transportation Index Fund reversed (IYT: 168.64) + \$ 4.18 or +2.5% rebounding, making back all of the losses of the previous week.

Index	Started Week	Ended Week	Change	% Change	YTD %
DJIA	21812.09	21987.56	175.47	+0.8%	11.3
Nasdaq	6265.64	6435.33	169.69	2.7%	19.5
S&P 500	2443.05	2476.55	33.50	1.4%	10.6
Russell 2000	1377.45	1413.57	36.12	2.6%	4.2
DJT	9133.75	9356.02	222.27	2.4%	3.5

US Dollar (DXYO: 92.83 +0.29 or +0.17% . The dollar struggled to hold but made back all of its losses the previous week.

Volatility (VIX: \$10.13 -\$ 1.15 or -10.2%) The volatility was weak, with a large decline indicating a favorable outlook for stocks. Stocks were strong during this usually difficult period of August through early September. This gauge measures options bets on the S&P 500 index.

CBOE OEX Volatility Index (VXO-X 8.94) - \$ 1.34 or - 13% The index came back down below its 200 and 50 dayday price moving averages as stocks rallied.

The UVXY, (\$ 28.94) or - \$ 1.94 - 6.3%; Continued Declining, down two weeks consecutively totaling more than 10 points or descending 25.7%, challenging the lows for the year.

The U.S. Oil Fund (USO : \$9.67) -0.08 or -0.8% struggling to hold its 50 day moving average as the market works off huge supplies.

Semiconductors (SMH: \$ 89.00) + \$ 2.70 or + 3.1%; Rallied to almost the 2017 high reached June 8th at \$ 89.72.

Natural Gas (3.06) +0.14 U.S. natural gas consumption bounced a bit from a 2-year low as the result of hot weather. According to the EIA, US natural gas consumption will average only 72.6 Bcf per day in 2017 and 75.8 Bcf per day in 2018. This news release caused a slump in natural gas prices and probably made the low point for the year. The UNG rallied to \$ 6.79 up \$ 0.30 for the week a gain of 4.6%.

Russell 2000 (IWM: \$ 140.52) + 3.64 or + 3.7%: Rallied above the 50 day moving average after descending down to the critical 200 day price moving average where it found good support.


The GDX, the VanEck Gold Miners ETF (GDX: 24.78) + 1.35 or +5.8% Continued its ascent after breaking above and finding support at the 200-day m.a.It is now less than a dollar from its yearly high of \$ 25.71.

Alibaba (BABA: \$ 171.04) - \$ 0.70 or -0.4%; It rebounded nicely from oversold conditions remaining solidly bullish. Our original buy recommendation on April 11th was \$ 111.00/share.

Amazon (AMZN: \$ 978.25) +32.99 or +3.5%: Climaxed at \$1083.31 and since dropped 140 points during the past three weeks seeking a new direction.

Crude OIL (\$47.87) -0.64 -1.3% The strong world economy is supportive in utilizing huge supplies.

Gold (GLD: \$ 122.71 +\$ 0.41 or +0.3% **Found new support at the \$ 120.50 level** and then rallied impressively to close above all moving averages moving well above the year's highs achieved June 7th. It looks impressive in all major currencies. Fed uncertainty has helped firm up gold prices, while popularity of gold has plummeted in China and India. But despite this massive decline in the largest single source of gold demand, prices have proved resilient, partly due to strong investor demand; also, in the face of the world-wide political instability, plus the delay of ongoing interest-rate hikes by the US.



ECONOMICS


GDP Increases at a 3% rate: The Second Estimate for Second Quarter GDP showed that real GDP increased at an annual rate of 3.0% in the second quarter, even above the Briefing.com consensus of +2.7% versus the advance estimate of 2.6%. The GDP Price Deflator was left unchanged at 1.0%, as expected. The overall GDP growth rate was the first with a 3-handle on it since the first quarter of 2015. The key takeaway from the report is that it was driven by a pickup in both consumer and business spending, which is typically a good mix for accelerating economic growth.

The upward revision was directly related to the upward revisions to personal consumption expenditures (from 2.8% to 3.3%) and gross private domestic investment (from 2.0% to 3.6%), which was led by nonresidential fixed investment (from 5.2% to 6.9%). Government spending was revised down (from 0.7% to -0.3%).

There was basically no change in private inventories, so real final sales of domestic product checked in at 3.0%, which was the highest rate since the second quarter of 2015.

Category	Q2	Q1	Q4	Q3	Q2
GDP	3.0%	1.2%	1.8%	2.8%	2.2%
Inventories (change)	\$1.8B	\$1.2B	\$63.1B	\$17.6B	\$12.2B
Final Sales	3.0%	2.7%	0.7%	2.6%	2.9%

PCE	3.3%	1.9%	2.9%	2.8%	3.0%
Nonresidential Inv.	6.9%	7.1%	0.2%	3.4%	3.3%
Structures	6.2%	14.8%	-2.2%	14.3%	0.5%
Equipment	8.8%	4.4%	1.8%	-2.1%	-0.6%
Intellectual Property	4.9%	5.8%	-0.4%	4.2%	11.1%
Residential Inv.	-6.5%	11.1%	7.1%	-4.5%	-4.8%
Net Exports	-\$613.4B	-\$622.2B	-\$631.1B	-\$557.3B	-\$572.4B
Export	3.7%	7.3%	-3.8%	6.4%	2.8%
Imports	1.6%	4.3%	8.1%	2.7%	0.4%
Government	-0.3%	-0.6%	0.2%	0.5%	-0.9%
GDP Price Index	1.0%	2.0%	2.0%	1.4%	2.4%




Personal Income increased 0.4% in July. The Briefing.com consensus expected +0.3%, led by a nice 0.5% increase in wages and salaries, while personal spending increased 0.3%. The Briefing.com consensus expected a +0.4% increase on the heels of an upwardly revised 0.2% increase from 0.1% for June. The personal savings rate dipped from 3.6% to 3.5%.

The PCE Price Index and core PCE Index, which excludes food and energy, were both up 0.1% in July. Those increases left the PCE Price Index up 1.4% year-over-year, unchanged from the 12-months ending in June, and the core PCE Price Index up 1.4%, down from 1.5% in June.

The key takeaway from the report was that inflation pressures remained subdued, which suggests to market participants that expectations for another rate hike this year can also remain subdued.

Category	JUL	JUN	MAY	APR	MAR
Personal Income					
Total Income	0.4%	0.0%	0.3%	0.1%	0.3%
Wage and Salary	0.5%	0.5%	0.1%	0.6%	0.1%
Disposable Income	0.3%	0.0%	0.4%	0.2%	0.3%
Savings Rate	3.5%	3.6%	3.8%	3.7%	3.9%
Personal Consumption					
Total (Nominal)	0.3%	0.2%	0.2%	0.3%	0.5%
Total (Real, Chain \$)	0.2%	0.2%	0.3%	0.1%	0.7%
Core PCE Deflator					
Month/Month	0.1%	0.1%	0.1%	0.2%	-0.2%



Source: Bureau of Economic Analysis; updated 08/31/17

Briefing.com

CYCLES

Since 1950, September has been the worst performing month of the year for DJIA (-0.8%), S&P 500 (-0.5%), NASDAQ (-0.5%) (since 1971), Russell 1000 (-0.6%), and Russell 2000 (-0.5%) (since 1979). September was sold-off four years straight from 1999-2002 after four solid years from 1995-1998 during the dot.com bubble madness. In post-election years, September's overall rank improves modestly in post-election years going back to 1953 (second, third or fourth worst month depending on index). Average losses are little changed. Although September 2001 does influence the average declines, the fact remains DJIA and S&P 500 have declined in 9 of the last 16 post-election year Septembers.

Post-Election Year September since 1953				
	Rank	Avg %	Up	Down
DJIA	9	-0.7	7	9
S&P 500	9	-0.6	7	9
NASDAQ*	10	-0.3	7	4
Russell 1K**	10	-0.7	4	5
Russell 2K**	11	-0.7	6	3
* Since 1973, ** Since 1981				
© StockTradersAlmanac.com. All rights reserved.				

In recent years, Labor Day has become the unofficial end of summer and the three-day weekend has become prime vacation time for many. Business activity ahead of the holiday was more energetic in the

old days. From 1950 through 1977 the three days before Labor Day pushed the DJIA higher in twenty-five of twenty-eight years. Bullishness has since shifted to favor the two days after the holiday as opposed to the days before. DJIA has gained in 16 of the last 23 Tuesdays and 16 of the last 22 Wednesdays following Labor Day. This year the Dow Jones Industrials began the prior-Labor Day week at 21,813.67 and ended at 21,987.56, up 173.89

Although the month has opened strong this year, up \$ 4.90 the first day of trading, and it has been up 13 of the last 22 years. Traders and Fund managers are usually negative this time of the year, and looking for short positions as the markets climb a wall of worry. Traders have been looking for methods to modify their portfolios to be hedged at the end of the third quarter.

Recent substantial declines occurred following the terrorist attacks in 2001 (Dow: -11.1%) and the collapse of Lehman Brothers in 2008 (Dow: -6.0%). Solid September gains in 2010; DJIA's 7.7%, S&P 500's 8.8% were the best since 1939, but the month suffered nearly the same magnitude declines in 2011, confirming that September can be a volatile month.

September Triple Witching week (September 11th-17th) is generally bullish with S&P 500 advancing twice as many times as declining since 1990, but it has suffered some sizable losses. Triple-Witching Friday was essentially a sure bet for the bulls from 2004 to 2011, but has been a loser four or five of the last five years, depending on index. The week after Triple Witching has been brutal, down 22 of the last 27, averaging an S&P 500 loss of 1.0%. In 2011, DJIA and S&P 500 both lost in excess of 6%.

SEPTEMBER 2017

Sector Seasonalities: Long = (L); Short = (S)

Start: Oil (S)

In Play: Biotech (L), High-Tech (L), Semiconductor (S),
Utilities (L), Materials (S), Gold & Silver (L), Transports (S)

Finish: None

MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SAT	SUN
<p>*Tuesdays: Weekly Chain Store Sales & Avg Hourly Earnings</p> <p>*Wednesdays: Oil & Gas Inventories</p> <p>*Thursdays: Wkly Unemployment Report, Wkly Mutual Fund Flows & Weekly Natural Gas Storage Report</p> <p>*Fridays: Weekly Leading Economic Index</p> <p><i>*Except holidays</i></p>				<p>1 First Trading Day, S&P Up 13 of Last 22</p> <p>Construction Spending ECRI Future Inflation Index Employment Rate ISM Index Semiconductor Billings U Mich Consumer Sentiment Vehicle Sales</p>	2	3
<p>4</p> <p>Labor Day (Market Closed)</p>	<p>5</p> <p>Day After Labor Day, Dow Up 16 of Last 23</p> <p>Factory Orders</p>	<p>6</p> <p>Average September Gains Last 21</p> <p>Dow: -0.7% Up 10 Down 11 Rank #9</p> <p>Beige Book Int'l Trade Deficit ISM Non-Mfg. Index</p>	<p>7</p> <p>S&P: -0.3% Up 11 Down 10 Rank #10</p> <p>Productivity and Costs</p>	<p>8</p> <p>NAS: -0.1% Up 12 Down 9 Rank #10</p> <p>Consumer Credit Wholesale Trade</p>	9	10
<p>11  In Memory</p> <p>Monday of Triple Witching Week, Russell 2000 Down 11 of Last 18</p>	<p>12 </p> <p>Expiration Week 2001, Dow Lost 1370 Points (14.3%), 2nd Worst Weekly Point Loss Ever, 5th Worst Week Overall</p>	<p>13 </p> <p>PPI Treasury Budget</p>	<p>14</p> <p>CPI</p>	<p>15 </p> <p>Triple Witching Day, Dow Up 10 of Last 15</p> <p>Business Inventories Industrial Production Retail Sales U Mich Consumer Sentiment</p>	16	17
<p>18 </p>	<p>19</p> <p>SEMI Book to Bill Ratio Housing Starts Import/Export Prices</p>	<p>20</p> <p>Existing Home Sales FOMC Meeting</p>	<p>21</p> <p>Rosh Hashanah</p> <p>Leading Indicators Philadelphia Fed Survey</p>	<p>22 </p>	23	24
<p>End of September Prone to Weakness From End-of-Q3 Institutional Portfolio Restructuring Week After September Triple Witching Dow Down 21 of Last 27 Average Loss Since 1990, 1.1%</p>						
<p>25 </p> <p>NAHB Housing Mkt Index</p>	<p>26</p> <p>Consumer Confidence New Home Sales</p>	<p>27 </p> <p>Durable Goods</p>	<p>28 </p> <p>Agricultural Prices GDP - Q2 Final</p>	<p>29 </p> <p>Last Day of Q3 Dow Down 14 of Last 20</p> <p>Chicago PMI Personal Income/Spending U Mich Consumer Sentiment</p>	<p>30</p> <p>Yom Kippur</p>	1
<p><i>Economic release dates obtained from sources believed to be reliable. All dates subject to change.</i></p>						
<p> Bull symbol signifies a favorable day based on the S&P 500 Rising 60% or more of the time on a particular trading day 1996-2016</p>			<p> Bear symbol signifies an unfavorable day based on the S&P 500 Falling 60% or more of the time on a particular trading day 1996-2016</p>			

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.51)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and the latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare GmbH**, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$ 11.35) + \$ 0.34 or +3.1%:

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 55.3% versus the Dow Jones +9.7%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.

Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled. When the company passed the \$ 500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 3.39*

Revenues from products sold increased quarter to quarter to \$ 540,372 this year up from \$ 510,963 in 2016, an increase of \$ 29,409 or 6% primarily due to higher revenue from grant related activities and instrument sales. Products and services revenue increased to \$ 480,400 in 2nd Qtr 2017 compared to \$ 474,187 during the same period of 2016.

The company recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical

operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. **PBIO** has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called **pressure cycling technology, or PCT**, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.


The **PBIO** pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their **PCT Sample Preparation System (“*PCT SPS*”).**

The **PBIO** pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
 - *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
 - *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*
 - *and immunodiagnosics (useful in the development and detection of biomarkers).*

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.



Leo Motors (LEOM: \$0.15)* is the premier company that develops electric vehicles (EV's) that can travel at higher speed along roads and freeways. After 10 years of field tests, the Company has surpassed obstacles of speed, torque and reliability over other e-vehicles. Leo motors has developed an array of electric vehicles and boats, including armored military vehicles, sports cars, utility trucks, passenger buses and electronic title water boats.

Leo Motors primary division, LGM, is producing and marketing electric boats (E- boats). LGM is the one of the few companies in the world that produces a safe high power electric boat. March 2017, LGM

unveiled their proprietary new electric powerboat propulsion system at the 2017 Busan Boat Show in Korea. The new LGM powerboat electric propulsion system produces up to 660 horse power (HP) and is compatible with most power boats and yachts.

LGM's electric inboard and outboard propulsion systems now range from 40 HP to 700 HP and also includes their Sailing Generation System that uses wind to recharge batteries while under way, eliminating conventional charging processes. LGM is communicating with potential partners in America for their conversion enterprise.

LGM will enter into the U.S. market this year providing electric conversion services. LGM will replace old internal combustion engine yachts and powerboats to the LGM electric power system.

Smart E-Vehicle Technology

LEO's proprietary electronic vehicle ecosystem has intelligent software which controls a cloud system. LEO developed the Vehicle to Everything (V2E) platform which uses smart technology to manage a cloud in the operating system (OS). The integrated OS allows connectivity with a smart device for improved driving solutions. The smart applications help reduce battery exchange recharge time, and provides roadside assistance. A GPS application uses satellite and mobile networks connected to Android systems using a Bluetooth®. The app sends updates, battery status and swap service information.

Skinvisible (SKVI: \$ 0.025)* Skinvisible Pharmaceuticals, Inc., is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

NightFood, Inc. (NGTF 0. 155)* Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat. People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or "bites"

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies, Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free.

Fundamental Analysis: Stocks To Buy with Stops: Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition some have been stopped out with small losses.

As indicated on the table below, balance is critical. And we have exited most long positions. Alibaba and Boeing have made a great deal of points. We did take profits. We are looking for a place to re-buy. We have no position in Alcoa AA. If long, raise stops to \$ 35 as a risk point. Flushing Financial FFIC fell below the 50 day price moving average on March 3rd, and again on August 9th and now has even breached the 200 day m.a. We have sold the Flushing Financial as indicated on the table. We have been looking for a place to buy Bristol Myers. Hecla Mining might be a speculative buy at a double bottom from July 7th at about \$ 4.82-86. We took profits on ENZ but still want to be long at lower prices. The HDGE is a trading vehicle. The recent rally to the 13 day moving average at \$ 8.77 was a reasonable place to sell. The decline to the 50 day m.a. at \$ 8.62 is a buying opportunity. It is a good long or offset against portfolio positions.

	Name	Business Description	PE	P/S	MV mln	Current Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	Largest on-line book seller in China; more of a retailer than Amazon	50.67	13.21	275.5B	171.04	Bought @ \$ 111 on 4/7/17 opening	Profits taken 160 -170
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	978.25 stopped out	Sold on stop 976	No position See July mkt letters
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and	9.7	2.5	1.39B	46.58 Stopped	Bought 39.10	49.40x on June 29 th

		communications				out 49.40	01/28/17	
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.85	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	26.55 Stopped out28.9 0 05/04	19.40 10/31/16	Looking for place to re-buy
BMV	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	59.90 No position	Possibly in a dbl top area	If bought sell at 53.90x
BA	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	240.33	Long at 132 10/04/16	210x
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.33 Look for re-entry lower	No Position	A troubled long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3.5	592Mln	27.49	19.10 bought 06/27/16	50 day m.a. at 27.45; sell belowj
HDG E	Bear ETF	Seems to stabilize at the \$ 8.50 level	NA	NA	176.8Mln	8.62	long 8.54 8/03/17	8.44x lowering stop loss
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	45.04	21.15 originally bought 2/8/16	\$ If long use \$ 41 stop
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	11.35	Bought at 5.13 10/7/16	<i>Sold on Opening Monday 4/3/17 Sold 8.43</i>
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	24.09	Bought at 15.42 9/30/16	23.60x stopped 3/21/17

Mike King
Princeton Research
3887 Pacific Street, Las Vegas, Nevada 89121

Or: Charles Moskowitz
CAM@MoneyInfo-LLC.com
617 827 1296

Phone: (702) 650-3000
Cell: (702) 493-3683
mike@princetonresearch.com or cam@princetonresearch.com
Visit: www.princetonresearch.com

Disclaimer* Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. . Princeton is paid \$ 2500 per month by Pressure

Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors. Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

UNSUBSCRIBE

To unsubscribe from this newsletter, please reply to this email with UNSUBSCRIBE in the subject line. We will send you a confirmation upon completing your request.